APLT - Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting | Benzinga
- The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in patients with diabetic cardiomyopathy (DbCM)
- Baseline data from ARISE-HF shows patients with DbCM exhibit reduced cardiac functional capacity resulting in decreased physical activity
NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will participate in a Symposium presentation, entitled Diabetic Cardiomyopathy (DbCM): a severe complication of diabetes, at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting to take place October 2-6, 2023 in Hamburg, Germany and online.
"Patients with diabetes are at a high risk of developing overt heart failure even when optimal glucose control is achieved," said Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics. "Diabetic Cardiomyopathy (DbCM) is a severe disease affecting approximately 20% of patients with diabetes. The Phase 3 ARISE-HF study is investigating the potential benefit of AT-001 in treating DbCM, and we look forward to the data readout later this year."
Symposium presentation agenda
Diabetic Cardiomyopathy (DbCM): A Severe Complication of Diabetes
Thursday, October 5
5:30PM - 5:35PM
Introduction
Stefano Del Prato, MD, Chief of the Section of Diabetes, ...